Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q2 FY2023
As of Dec 31, 2022
Q1 FY2023
As of Sep 30, 2022
Q4 FY2022
As of Jun 30, 2022
Q3 FY2022
As of Mar 31, 2022
Q2 FY2022
As of Dec 31, 2021
Q1 FY2022
As of Sep 30, 2021
Q4 FY2021
As of Jun 30, 2021
Q3 FY2021
As of Mar 31, 2021
Q2 FY2021
As of Dec 31, 2020
Q1 FY2021
As of Sep 30, 2020
Q4 FY2020
As of Jun 30, 2020
Q3 FY2020
As of Mar 31, 2020
Q2 FY2020
As of Dec 31, 2019
Q1 FY2020
As of Sep 30, 2019
Q4 FY2019
As of Jun 30, 2019
Q3 FY2019
As of Mar 31, 2019
Q2 FY2019
As of Dec 31, 2018
Q1 FY2019
As of Sep 30, 2018
Q4 FY2018
As of Jun 30, 2018
Q3 FY2018
As of Mar 31, 2018
ASSETS
Current assets
Cash and cash equivalents
Marketable securities
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Intangible assets, net
Strategic investments
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable
Accrued expenses
Deferred revenue
Total current liabilities
Long-term liabilities
Financing obligation
Deferred revenue
Other liabilities
Total liabilities
Common stock, $0.001 par value; authorized 100,000,000 common shares; issued and outstanding 41,965,948 at December 31, 2022 and 40,965,202 at June 30, 2022, respectively
Additional paid in capital
Accumulated other comprehensive income
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support